CAL02

About Combioxin

Combioxin is dedicated to revolutionizing the treatment of severe infections and immune dysfunction in intensive care. Its core technology uses proprietary engineered liposomes to capture and neutralize bacterial toxins, offering a novel mechanism against both Gram-positive and Gram-negative pathogens. The company has achieved significant regulatory milestones for CAL02, initiated a global Phase 2b study, and secured a worldwide out-licensing agreement with Eagle Pharmaceuticals, positioning it to address a critical unmet medical need with high mortality and cost.

About Lipidor

Lipidor is a private, pre-revenue biotech firm leveraging its AKVANO® technology platform to reformulate drugs with poor solubility and create novel topical treatments. The company's most advanced program targets psoriasis and is in Phase III clinical development, positioning it as a near-term value driver. With a lean operational model, Lipidor aims to out-license its formulations to larger pharmaceutical partners for commercialization. The company's success hinges on clinical validation of its platform and securing strategic partnerships for its pipeline assets.

Therapeutic Areas